Cross Linking News and Research

RSS

Scientists to reveal latest research breakthroughs at 'Chemistry and Health' conference

To mark the International Year of Chemistry, the 94th Canadian Chemistry Conference and Exhibition will take place at the Palais des congr-s de Montr-al from June 5 to 9, 2011. The gathering is the biggest ever annual event in Canada to focus on science and the practice of chemistry.

4 Jun 2011

$Avedro completes two Phase III corneal cross-linking studies in keratoconus, ectasia post-refractive surgery$

Avedro completes two Phase III corneal cross-linking studies in keratoconus, ectasia post-refractive surgery

Avedro, Inc. today announced the completion of all one-year follow-up visits for patients enrolled in its two multi-center Phase III studies evaluating the safety and efficacy of corneal collagen cross-linking for the treatment of progressive keratoconus and ectasia following refractive surgery.

18 May 2011

Paulig Eye Surgery Center provides non-invasive alternative to keratoconus patients

The Paulig Eye Surgery Centre announces today that it has acquired advanced technology for performing Keraflex KXL, a new, non-invasive, non-surgical treatment for keratoconus. Surgeons at the Paulig Eye Surgery Centre will immediately begin treating patients using Avedro, Inc's Keraflex and KXL Systems.

3 May 2011

Detection of latent fingerprints through release of fluorescein from a nanofiber mat

When a forensic agent dusts a surface with powder or exposes it to the vapors of an iodine chamber, mystery fans know what is going on: This is how latent fingerprints are made visible so that they can be compared to those of a suspect. Su Chen and a team at Nanjing University of Technology have now developed a new process for especially rapid and simple detection of fingerprints. As the Chinese researchers report in the journal Angewandte Chemie, all it takes is a special nanofiber mat that is pressed onto the suspect surface and briefly treated with hot air—the fingerprints appear as red ridge patterns.

11 Apr 2011

Covidien to present new data on hernia, abdominal wall repair products at San Francisco

Covidien, a leading global provider of healthcare products, announced that new data on its hernia and abdominal wall repair products will be presented at Hernia Repair 2011, the 14th Annual Meeting & Scientific Program of the American Hernia Society.

15 Mar 2011

First patient treated in KUR-023 pilot clinical trial to assess safety and efficacy of product candidate

Kuros Biosurgery AG, a biotechnology company focused on the development of novel biomaterials and bioactive-biomaterial combination products for trauma, wound and spinal indications, announced today that it has treated the first patient in a pilot clinical trial investigating the safety and efficacy of KUR-023, its novel dural sealant product candidate.

28 Feb 2011

Protein cross-linking enzymes in foods can affect physiological characteristics

Protein modification via enzymatic cross-linking is an attractive way for altering food structure so as to create products with increased quality and nutritional value. These modifications are expected to affect not only the structure and physico-chemical properties of proteins but also their physiological characteristics, such as digestibility in the GI-tract and allergenicity.

10 Feb 2011

Cell binding mechanism can lead to new treatments for skin diseases, lethal heart defects

A University of Manchester scientist has revealed the mechanism that binds skin cells tightly together, which he believes will lead to new treatments for painful and debilitating skin diseases and also lethal heart defects.

From The University of Manchester 21 Jan 2011

Study shows delivering cancer drug in hydrophobic nanoparticle is a safe and effective prostate cancer therapy

Researchers at MIT and Brigham and Women's Hospital have shown that they can deliver the cancer drug cisplatin much more effectively and safely in a form that has been encapsulated in a nanoparticle targeted to prostate tumor cells and is activated once it reaches its target.

12 Jan 2011

Neomend receives CE Mark for ProGEL PLATINUM Surgical Sealant

Neomend, Inc., an innovator in sealant and adhesion-prevention products for the surgical marketplace, announced it has received the European Union CE Mark for the company's ProGEL® PLATINUM Surgical Sealant.

10 Jan 2011

MiMedx awarded QTDP grant for CollaFix drug delivery device

MiMedx Group, Inc., an integrated developer, manufacturer and marketer of patent protected biomaterial-based products, announced today that it has been awarded a Qualifying Therapeutic Discovery Project grant (QTDP) from the U.S. Government. The grant, in the amount of $244,479, has been made to defer some of the Company's research expenditures related to the development of its novel and patented technology, CollaFix™, as a drug delivery device.

2 Dec 2010

Avedro's KXL System for corneal cross-linking granted European CE Mark

Avedro, Inc., sponsor of two completed US FDA multi-center clinical trials for corneal cross-linking, today announced that its KXL™ System for performing accelerated corneal cross-linking (KXL) has received the European Union's CE Mark. The CE Mark certifies that the KXL System has met the EU's health and safety standards and opens the door to immediate commercialization across the European Economic Community and in other countries recognizing the CE Mark.

17 Nov 2010

InNexus receives $116,760 cash grant under QTDP program to develop DXL anti-cancer antibodies

InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.

8 Nov 2010

CR4354 antibody uses crosslinking mechanism to neutralize West Nile virus

Researchers have learned the structure that results when an antibody binds to the West Nile virus, neutralizing the virus by locking up its infection mechanism. The information could help scientists develop a vaccine against the mosquito-borne disease.

3 Nov 2010

Antigene therapy uses light energy to silence gene activity: Review article

Antigene therapy is a promising new treatment strategy that uses a DNA-based drug to pinpoint light energy to a target gene shutting down its activity.

22 Oct 2010

Covidien to showcase innovative surgical products at 96th ACS Clinical Congress

Covidien, a leading global provider of healthcare products, will preview new devices and showcase some of the Company's most innovative products at the 96th Annual Clinical Congress of the American College of Surgeons.

5 Oct 2010

Cornea and Laser Eye Institute to study CXL effectiveness in keratoconus patients

The Cornea and Laser Eye Institute, with Principal Investigator, Peter S. Hersh M.D., is conducting a research study to study the safety and effectiveness of corneal collagen crosslinking (CXL) using Riboflavin/Dextran and Hypotonic Riboflavin in patients with progressive keratoconus and corneal ectasia.

17 Sep 2010

Studies provide evidence for new approach to MRSA vaccines

Two recent studies provide evidence for a new approach to vaccines to prevent infections caused by drug-resistant Staphylococcus aureus -- better known as MRSA - the leading cause of skin and soft tissue, bloodstream and lung infections in the United States. One demonstrates a way to counteract the bacteria's knack for evading the immune system. The other shows how to disrupt the germ's tissue-damaging mechanism.

17 Aug 2010

Researchers discover enzyme crucial for DNA repair

Researchers have discovered an enzyme crucial to a type of DNA repair that also causes resistance to a class of cancer drugs most commonly used against ovarian cancer.Scientists from The University of Texas MD Anderson Cancer Center and the Life Sciences Institute of Zhejiang University in China report the discovery of the enzyme and its role in repairing DNA damage called cross-linking in the Science Express advance online publication of Science.

30 Jul 2010

InNexus Biotechnology, NCI amend Collaborative Agreement

InNexus Biotechnology Inc., a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL™) technology, today announced the Company and the National Cancer Institute (NCI), part of the U.S. National Institutes of Health (NIH), have amended the Collaborative Agreement announced on May 27, 2010, involving research on technologies developed by InNexus.

2 Jul 2010